Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015)
Aclaris Therapeutics' quarterly Preferred Stock Liabilities came in at $78.3 million in Q3 2015, up 113.5% quarter-over-quarter from $36.7 million in Q4 2014.
Aclaris Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $78.3 million in Q3 2015.
- For the quarter ending Q3 2015, Preferred Stock Liabilities changed N/A year-over-year to $78.3 million; the trailing twelve-month figure through Sep 2015 stood at $78.3 million (changed N/A YoY), and the FY2014 full-year result was $36.7 million, up 59.47% from the prior year.
- Preferred Stock Liabilities for Q3 2015 stood at $78.3 million, up from $36.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $78.3 million in Q3 2015, with the low at $36.7 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Aclaris Therapeutics | 586.09 Mn | 586.09 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 78.31 Mn |
| Dec 31, 2014 | 36.68 Mn |